26. HTLV-1-associated myelopathy Clinical trials / Disease details
Clinical trials : 29 / Drugs : 47 - (DrugBank : 29) / Drug target genes : 34 - Drug target pathways : 119
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02655471 (ClinicalTrials.gov) | July 1, 2017 | 16/11/2015 | Effect of Raltegravir in Patients With Acute Tropical Spastic Paraparesis - Human T-Lymphotropic Virus 1 Infection | Effect of Raltegravir in Patients With Myelopathy/Tropical Spastic Paraparesis Associated With Infection by Human T-Lymphotropic Virus 1 (HTLV-1). Pilot Study | HTLV-I Infections;Tropical Spastic Paraparesis | Drug: Raltegravir and Zidovudine | Universidad Peruana Cayetano Heredia | Merck Sharp & Dohme Corp. | Completed | 18 Years | N/A | All | 10 | Early Phase 1 | Peru |
| 2 | NCT01867320 (ClinicalTrials.gov) | September 5, 2013 | 21/5/2013 | Raltegravir for HAM/TSP | Pilot Study of Raltegravir, an Integrase Inhibitor, in Human T-Cell Lymphotrophic Virus-1(HTLV-1) Associated Myelopathy, Tropical Spastic Paraparesis (HAM/TSP) | HTLV-I Infection | Drug: Raltegravir | National Institute of Neurological Disorders and Stroke (NINDS) | NULL | Completed | 18 Years | N/A | All | 19 | Early Phase 1 | United States |
| 3 | NCT01620736 (ClinicalTrials.gov) | January 2012 | 25/1/2012 | Trial to Assess Effect of Raltegravir on HTLV-1 Proviral Load | Phase II Trial to Assess Effect of Raltegravir on HTLV-1 Proviral Load | Human T-cell Leukemia Virus Type 1 Infection | Drug: Raltegravir | Washington University School of Medicine | Merck Sharp & Dohme Corp. | Withdrawn | 18 Years | N/A | All | 0 | Phase 2 | United States |
| 4 | NCT01000285 (ClinicalTrials.gov) | September 2010 | 19/10/2009 | EPOCH Chemotherapy and Bortezomib for Associated T-Cell Leukemia Lymphoma | Phase I/II Trial of Dose-Adjusted EPOCH Chemotherapy With Bortezomib Combined With Integrase Inhibitor Therapy for HTLV-1 Associated T-Cell Leukemia Lymphoma | Leukemia-Lymphoma, Adult T-Cell | Drug: Bortezomib;Drug: Etoposide;Drug: Vincristine;Drug: Doxorubicin;Drug: Prednisone;Drug: Cyclophosphamide;Drug: Raltegravir | Washington University School of Medicine | NULL | Completed | 18 Years | N/A | All | 18 | Phase 1/Phase 2 | United States |